EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Outcomes of Lenalidomide-Dexamethasone in Combination With Radiotherapy in Solitary Plasmacytoma

Pierre Loap, Sebastien Laroze, Didier Bouscary, Marguerite Vignon, Youlia Kirova

International Journal of Radiation Oncology*Biology*Physics · 2026-10

DOI: 10.1016/j.ijrobp.2026.10.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-10. Verfasst von Pierre Loap und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Institut Curie, Paris, France; Imaging, Innovative Radiotherapy and System Medicine, UMR9029 CNRS, U1353 Inserm, Ve…. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Radiotherapy achieves excellent local control in solitary plasmacytoma, but systemic progression remains a major limitation. We evaluated the long-term association between lenalidomide-dexamethasone combined with radiotherapy and disease outcomes. MATERIALS AND METHODS: This retrospective analysis of a prospectively maintained database included 75 consecutive patients with solitary plasmacytoma treated between 2004 and 2025. All patients underwent bone marrow assessment, serum free light-chain testing, and magnetic resonance imaging, with PET/CT routinely incorporated into staging from late 2008 onward. Patients received radiotherapy alone (n=42) or radiotherapy combined with lenalidomide-dexamethasone (n=33). Primary endpoints were progression-free survival and multiple myeloma-free survival. Systemic progression-free survival, defined by progression to multiple myeloma, multiple plasmacytomas, or distant solitary plasmacytoma, was additionally evaluated. RESULTS: Median follow-up was 6.31 years. Only three local recurrences occurred. Lenalidomide-dexamethasone was associated with longer progression-free survival (HR, 0.315; 95% CI, 0.128-0.775; p=0.012), with 10-year rates of 71.8% versus 26.7% after radiotherapy alone. Among the six patients progressing after combined treatment, three (50.0%) developed multiple myeloma and three (50.0%) developed multiple plasmacytomas. Multiple myeloma-free survival did not differ significantly between groups (10-year rates, 86.6% vs 65.9%; p=0.19). CONCLUSION: Lenalidomide-dexamethasone combined with radiotherapy was associated with sustained improvement in progression-free survival in solitary plasmacytoma. These long-term findings support prospective evaluation of upfront lenalidomide-dexamethasone in combination with radiotherapy for solitary plasmacytoma.

Autor:innen und Institutionen

  • Department of Radiation Oncology, Institut Curie, Paris, France; Imaging, Innovative Radiotherapy and System Medicine, UMR9029 CNRS, U1353 Inserm, Versailles Saint-Quentin University, PSL Research University, Institut C…
  • Department of Radiation Oncology, Institut Curie, Paris, France.
  • Hematology Department, Hospital Cochin, Paris, France.

Zitieren

APA

Loap, P., Laroze, S., Bouscary, D., Vignon, M., & Kirova, Y. (2026). Long-Term Outcomes of Lenalidomide-Dexamethasone in Combination With Radiotherapy in Solitary Plasmacytoma. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.10.030

Vancouver

Loap P, Laroze S, Bouscary D, Vignon M, Kirova Y. Long-Term Outcomes of Lenalidomide-Dexamethasone in Combination With Radiotherapy in Solitary Plasmacytoma. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.10.030

BibTeX
@article{Loap2026,
  author = {Loap, Pierre and Laroze, Sebastien and Bouscary, Didier and Vignon, Marguerite and Kirova, Youlia},
  title = {Long-Term Outcomes of Lenalidomide-Dexamethasone in Combination With Radiotherapy in Solitary Plasmacytoma},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2026.10.030}
}
Kostenlos starten →